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a b s t r a c t
Friedreich ataxia (FRDA) is a progressive neurological disorder affecting approximately 1 in
29,000 individuals of European descent. At present, there is no approved pharmacological
treatment for this condition however research into treatment of FRDA has advanced
considerably over the last two decades since the genetic cause was identiﬁed. Current
proposed treatment strategies include decreasing oxidative stress, increasing cellular fra-
taxin, improving mitochondrial function as well as modulating frataxin controlled meta-
bolic pathways. Genetic and cell based therapies also hold great promise. Finally, physical
therapies are being explored as a means of maximising function in those affected by FRDA.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Friedreich ataxia (FRDA) is the most common of the inherited
ataxias with a prevalence of approximately 1 in 29,000
individuals [1,2]. In 96% of affected individuals a homozygous
GAA triplet repeat expansion in intron 1 of the FXN gene is the
cause of FRDA. The remainder are compound heterozygotes,
with a GAA expansion in one allele and a point mutation/
deletion/insertion in the other [3,4]. FXN encodes frataxin, a
mitochondrial protein involved in iron metabolism including
iron–sulphur cluster synthesis.* Corresponding author at: Bruce Lefroy Centre for Genetic Health R
Parkville, Victoria 3052, Australia.
E-mail address: martin.delatycki@vcgs.org.au (M.B. Delatycki).
https://doi.org/10.1016/j.pjnns.2018.02.003
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier SThe main clinical features of FRDA include gait and limb
ataxia, dysarthria, areﬂexia, extensor plantar responses,
posterior column dysfunction, cardiomyopathy and scoliosis
[4,5]. The average age of onset of symptoms is 10–15 years but
can be considerably earlier or later. The requirement for the
use of a wheelchair is on average 15 years after symptom
onset [6].
At present, there is no approved pharmacological treat-
ment for this progressive condition [7]. However, research into
potential pharmacological treatment for FRDA has advanced
considerably in the past two decades with many potential
therapeutic agents proposed to delay disease progression andesearch, Murdoch Children's Research Institute, Flemington Rd,
p. z o.o. All rights reserved.
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evaluation [8,9].
2. Neurological rating scales
One of the main challenges of measuring the progression of
FRDA, and therefore to measure the beneﬁt of any therapy, is
the clinical variability and heterogeneity of this slowly
progressive disorder. As effective therapeutic agents are likely
to delay disease progression, it is imperative that measures
used to detect clinically signiﬁcant changes are accurate [7].
Neurological function in FRDA is assessed using a range of
rating scales that are administered by trained clinicians. The
most common of these scales is the Friedreich Ataxia Rating
Scale (FARS) [10]. The International Cooperative Ataxia Rating
Scale (ICARS) and the Scale for the Assessment and Rating of
Ataxia (SARA) are two other widely used neurological rating
scales [11,12].
The FARS [10] is a clinical rating scale speciﬁc to FRDA. This
scale consists of three subscales measuring ataxia, activities of
daily living, and a neurological examination, and has good
inter-rater reliability indicating the degree to which raters
provide consistent estimates of the same behaviour is high
[10]. The ICARS [11] is comprised of four subscales measuring
posture and gait, kinetic function, speech and oculomotor
function, and has high inter-rater reliability [13]. The SARA is
the most recently developed tool in the rating of FRDA. This
scale encompasses eight items evaluating gait, stance, sitting,
speech, and limb kinetic function [12]. The use of the SARA is
increasing due to its ease and speed of administration,
especially when compared to the FARS and ICARS.
While rating scales provide a good indicator of disease
progression, they can be biased as they depend on adminis-
tration by clinicians. This can result in reduced sensitivity and
reliability [7,14]. Functional composites have therefore been
designed to measure disease severity in FRDA. The composite
most widely used in the evaluation of FRDA is the Friedreich
Ataxia Functional Composite (FAFC). This composite com-
prises the 25-foot walk test, the 9-hole peg test and the Sloan
low contrast letter acuity test [14]. Whilst functional compo-
sites are considered more objective, are easier to administer,
and have good inter- and intra-rater reliability, they suffer
from signiﬁcant ceiling effects which reduce sensitivity in
those individuals with more severe disease [15].
3. Pharmacological therapies in FRDA (Table 1)
3.1. Therapies that decrease oxidative stress and enhance
mitochondrial function
3.1.1. Idebenone
Mitochondrial dysfunction and oxidative tissue damage are
contributors to the pathology of FRDA [16,17]. The use of
antioxidants has thus been explored as a potential therapy for
the treatment of this condition.
Idebenone, an antioxidant and a synthetic analogue of
coenzyme Q10 [18], has been studied as a potential treatmentfor both the neurological and cardiac aspects of FRDA since
1999. Despite the fact it is generally well-tolerated and safe in
terms of adverse effects [19], results from studies have been
inconclusive [20–29]. Early studies used low-dose idebenone at
5 mg/kg/day [21–23] however higher doses of idebenone have
increasingly become used in clinical trials as these doses may
be required to demonstrate efﬁcacy. Several open-label low-
dose (5 mg/kg/day) idebenone trials showed improved echo-
cardiographic parameters in people treated with idebenone
that was maintained for up to ﬁve years [21–23], as well as
improved neurological symptoms in children as demonstrated
by the ICARS after three and six months [26].
In contrast, the four randomised double-blind placebo-
controlled trials that have been published have not demon-
strated robust evidence in terms of the beneﬁts of idebenone
on neurological or cardiac function. Only modest changes in
cardiac function were found in a year-long randomised
placebo controlled trial of 5 mg/kg/day of idebenone in 29
individuals with FRDA. There were some signiﬁcant improve-
ments (reduced interventricular septal thickness and left
ventricular mass) in the intervention compared to the placebo
group but there was no change reported in ejection fraction
[25].
The placebo-controlled NICOSIA (National Institutes of
Health Collaboration With Santhera in Ataxia) study of 48
children over six months demonstrated no signiﬁcant effect
on urinary 8-hydroxy-20-deoxyguanosine (8OHdG), the prima-
ry endpoint, or a change in FARS or ICARS (secondary
endpoints) [27]. However, a dose-dependent (5 mg/kg/day,
15 mg/kg/day and 45 mg/kg/day) improvement in the ICARS
was reported, indicating that higher doses could have
potential neurological beneﬁt [27].
A phase 3 double-blind placebo-controlled study (IONIA:
Idebenone Effects on Neurological ICARS Assessments) was
conducted in 70 paediatric participants over six months with
individuals administered either low (450 or 900 mg) or high
dose (1350 or 2250 mg) idebenone per day, depending on body
weight (≤ or > 45 kg) [28,29]. The IONIA study demonstrated no
reduction in left ventricular hypertrophy nor any improve-
ment in cardiac function. There was no signiﬁcant change in
neurological function as measured by the FARS or ICARS
[28,29].
The 12-month MICONOS (Mitochondrial Protection with
Idebenone In Cardiac Or Neurological Outcome Study) study
enrolled 232 mainly adult participants who received low,
medium, or high-dose idebenone [30]. No signiﬁcant differ-
ence in ICARS score between participants receiving treatment
and placebo were detected. There was also no difference
observed between the treatment and placebo groups in the
cardiac endpoints [30].
Despite these conﬂicting results, many individuals with
FRDA continue the use of idebenone as it is readily accessible
and has few adverse effects [20]. Neutropenia is reported as a
rare but signiﬁcant adverse event and should be monitored for,
particularly in individuals on high-dose idebenone [27,31].
3.1.2. Coenzyme Q10
Coenzyme Q10 is another antioxidant agent that has been
studied in the treatment of FRDA. An open-label study showed
an improvement in cardiac and skeletal muscle bioenergetics
Table 1 – Summary of pharmacological therapies in FRDA.
Pharmaceutical name Proposed mechanism Stage of development Study outcomes
Therapies that decrease oxidative stress and enhance mitochondrial function
Idebenone Antioxidant properties, prevents
damage to mitochondrial
membrane and supports
mitochondrial function
Randomised double-blind
placebo-controlled studies
Results have been inconclusive
with modest improvements seen in
some studies but not others;
unlikely to be approved as a
treatment for FRDA
Coenzyme Q10 Improves cellular bioenergetics,
decreases oxidative stress,
improves mitochondrial function
Randomised double-blind two
dose study
No beneﬁt found in high vs low dose
therapy
A0001 Antioxidant, chemically similar
to but more potent than
idebenone and coenzyme Q10
Randomised double-blind
placebo-controlled study
No difference in primary endpoint
(Disposition Index) however a dose-
dependent improvement was found
in the FARS score
EPI-743 Similar to A0001 – improves
mitochondrial function and
prevents oxidative stress
Randomised double-blind
placebo-controlled study,
followed by open-label study
No difference in primary endpoint
(low contrast visual acuity
assessment) however improvement
found in FARS neurological scale
(low dose vs placebo)
Omaveloxolone (RTA 408) Nrf2 activator – reduces
intracellular oxidative stress and
mitochondrial damage, increases
mitochondrial respiration and
biogenesis
Randomised double-blind
placebo-controlled study
Study is currently underway
RT001 Deuterised polyunsaturated fatty
acid (dPUFA) – reduces oxidative
stress in mitochondria therefore
increasing ATP production
Randomised double-blind study Primary safety, tolerability,
pharmacodynamic endpoints met;
full results to be published
Thiamine (vitamin B1) Involved in energy metabolism,
oxidative stress and potentially
neuroprotective
Open-label study Improvement found in SARA
scores, return of deep tendon
reﬂexes reported in 57% of
participants
Pioglitazone PPARg agonist – increases
frataxin protein levels, anti-
oxidant properties
Proof of concept study Full results to be published
L-Carnitine and creatine Involved in fatty acid transport in
mitochondria, alters levels of
membrane proteins in cerebellar
mitochondria therefore reducing
oxidative stress
Randomised placebo-controlled
crossover study, followed by
open-label study
No differences in ICARS scores or
echocardiographic measures in
treatment group compared to the
placebo group; open-label study is
ongoing
Anti-inﬂammatory therapy
Methylprednisolone A steroid that has anti-
inﬂammatory properties, may
alter oxidative damage caused by
frataxin deﬁciency
Open-label study Study is currently underway
Iron chelators
Deferiprone Iron chelator – removes surplus
iron therefore decreasing
oxidative stress and cellular
damage
Randomised double-blind
placebo-controlled study
No differences in FARS scores;
participants on higher doses found
to have greater progression in FARS
score than the placebo group.
Frataxin level modiﬁers
Erythropoietin Increases frataxin levels by a
post translation mechanism
Randomised double-blind
placebo-controlled study
No difference in frataxin levels or
SARA scores between treatment
and placebo group
Carbamylated erythropoietin A modiﬁed form of EPO that has
minimal erythropoietic
properties
Randomised placebo-controlled
study
No improvements in frataxin levels,
FARS or SARA scores
Ubiquitin competitors Blocks ubiquination of frataxin
therefore increasing intracellular
frataxin levels
Animal studies Studies are currently underway
CTI-1601 Delivery system (trans-activator
transcription, TAT) that
transports synthetic frataxin
directly into mitochondria
Animal studies Mean lifespan in mice increased by
53%, improvement shown in
cardiac function; given orphan drug
designation and currently being
developed as a treatment.
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Agents that increase FRDA gene expression
RG2833 An HDAC inhibitor, increases histone
acetylation resulting in increased
frataxin levels
Randomised double-blind
placebo-controlled study
Increased FXN gene
expression reported however
toxic metabolites
found indicating safety concerns
Nicotinamide An HDAC inhibitor, increases histone
acetylation resulting in increased
frataxin levels
Open-label dose-escalation
study
Upregulation in frataxin expression
found however no improvements
in clinical measures; randomised,
double-blind placebo-controlled
study is planned.
Interferon gamma Cytokine that that increases frataxin
mRNA and protein
Randomised, double blind
placebo-controlled study
No difference in primary endpoint
(modiﬁed FARS score) found when
compared to placebo
Resveratrol Natural phenol and antioxidant,
increases FXN gene expression
Open-label study Improvement found in oxidative
stress marker, FARS, ICARS,
hearing and speech outcome
measures however little change
in primary endpoint (PBMC frataxin
levels); randomised placebo-controlled
study is planned.
Granulocyte-colony stimulating
factor and stem cell factor
Cytokines with neuroprotective
effects, increases frataxin levels
and reduces inﬂammation
Animal studies Improvement shown in motor
coordination and locomotor activity
in mouse models
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2100 IU/day vitamin E in a study of 10 individuals with FRDA.
After three months of treatment, the maximum rate of skeletal
muscle mitochondrial ATP production increased to 139% of
baseline values [32]. An open-label extension study demon-
strated signiﬁcant improvement in cardiac and skeletal
muscle energy metabolism that was maintained throughout
a study period of 47 months [33]. A two-year double-blind
randomised study of high and low dose coenzyme Q10 and
vitamin E, without a placebo group, was conducted to
ascertain the potential of these agents to modify clinical
progression in FRDA [34]. There was no difference in ICARS
scores, the primary outcome measure, between the high
(600 mg/day of coenzyme Q10 and 2100 IU/day of vitamin E)
and low dose (30 mg/day coenzyme Q10 and 24 IU/day vitamin
E) groups indicating that high dose therapy provided no
additional beneﬁt when compared to low dose therapy [34].
3.1.3. A0001
Another antioxidant that has undergone clinical testing is
A0001 (a-tocopherylquinone) which is structurally similar to
coenzyme Q10 and idebenone. It is more potent than these two
agents and was therefore proposed to be more efﬁcacious [35].
The primary endpoint of a double-blind randomised placebo-
controlled trial of 31 adults was the Disposition Index, a widely
used measure of beta-cell function that deteriorates before
diabetes mellitus development. Participants on this four-week
study received placebo, low-dose A0001 (510 mg/day), or a
high-dose A0001 (750 mg/day). There was no statistical
difference in the Disposition Index between individuals
receiving A0001 and the placebo group, however a dose
dependent improvement in the FARS score was noted [36].
3.1.4. EPI-743
Following on from A0001, EPI-743 (a-tocotrienolquinone) was
subsequently developed as a potent antioxidant with the aimof treating inherited mitochondrial respiratory chain disorders
by improving mitochondrial function. EPI-743 is reported to be
one to ten thousand fold more potent than coenzyme Q10 and
idebenone in preventing oxidative stress in ﬁbroblast assays
[37,38]. EPI-743 has been tested in individuals with mitochon-
drial diseases including Leigh Syndrome and Leber Hereditary
Optic Neuropathy with clinical improvement demonstrated
without serious adverse events [39,40].
A six-month placebo-controlled multicentre study of EPI-
743 in 63 adults with FRDA was conducted [41]. Participants
received placebo, 600 mg/day EPI-743 or 1200 mg/day EPI-743.
This was then followed by an 18-month open-label extension
study where all participants received EPI-743 therapy. The
primary endpoint of low contrast visual acuity assessment
was not met, however an improvement in the neurological
examination subscale of the FARS was found in participants
administered low-dose EPI-743 when compared to the placebo
group ( p = 0.047) at 6 months. Treatment over 18 months
demonstrated signiﬁcant improvement in neurological out-
comes, and treatment was found to be well tolerated [41]. EPI-
743, at 1200 mg/day, has also been tested in people with FRDA
who are compound heterozygous for a FXN GAA repeat
expansion and a point mutation in an 18-month open-label
study [42]. There were signiﬁcant improvements in neurologi-
cal function as assessed by the FARS indicating potential
beneﬁt in this subgroup of individuals.
3.1.5. Nuclear factor erythroid-derived 2-related factor 2
(Nrf2) activators
Nuclear factor erythroid-derived 2-related factor 2 (Nrf2)
function is deﬁcient in FRDA [43], with Nrf2 deﬁciency leading
to faulty mitochondrial fatty acid oxidation and ATP produc-
tion [44]. Nrf2 activation is hypothesised to increase mito-
chondrial respiration and biogenesis [45], reduce intracellular
oxidative stress, and repair mitochondria damage [46]. RTA
408 (Omaveloxolone) is an Nrf2 activator that is currently being
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comparing 150 mg/day RTA 408 to placebo (https://
clinicaltrials.gov/ct2/show/NCT02255435).
3.1.6. RT001 (dPUFA)
Polyunsaturated fatty acids (PUFAs) are fatty acids that are
essential to the structure and function of lipid membranes.
PUFAs are prone to oxidative injury and it has been postulated
that this damage can lead to mitochondrial dysfunction [47].
By replacing hydrogen molecules with a hydrogen isotope
known as deuterium, PUFAs can be strengthened and, in the
process, protect the cells from oxidative damage. RT001 is a
deuterised PUFA (dPUFA) which has been tested in 18
individuals with FRDA in a randomised double-blind study.
The study was conducted over 28 days with participants
administered 1.8 g or 9 g per day of RT001 or an RT001
comparator. All primary safety, tolerability and pharmacody-
namics endpoints of the study were reportedly met [48]. Full
results have not been published.
3.1.7. Thiamine
Thiamine (vitamin B1) has recently been proposed as a therapy
for FRDA. Thiamine is important in central and peripheral
nervous system functioning. Thiamine also plays a role in
oxidative stress and is potentially neuroprotective [49–51]. An
open-label study reported improved neurological function in
34 individuals with FRDA administered 100 mg thiamine
intramuscularly every three to ﬁve days for three months
[52]. An open-label study of 100 mg thiamine twice weekly for
up to 24 months in 34 individuals with FRDA was therefore
conducted [53]. There were no reported serious adverse events.
The investigators found an improvement in SARA scores
(mean score at baseline was 26.6  7.7 compared to 21.5  6.2
at the ﬁnal visit, p < 0.02) and reported the return of deep
tendon reﬂexes in 57% of the study participants after three
months of treatment. Swallowing difﬁculties were reduced in
over 60% of individuals who reported this morbidity.
3.1.8. PGC-1a modulation
The down-regulation of the peroxisome proliferator activated
receptor gamma (PPARg) coactivator 1a (PGC-1a) has been
shown to inhibit the antioxidant response in FRDA [54]. It is
postulated that this effect can be restored by PPARg agonists
[55]. Pioglitazone is a PPARg agonist that is commonly used in
the treatment of type II diabetes [54]. A proof of concept study
exploring the effects of pioglitazone in FRDA over two years
has been completed (https://www.clinicaltrials.gov/ct2/show/
NCT00811681), with participants receiving pioglitazone at a
starting dose of 15 mg/day and up to 45 mg/day. Results have
not been published.
3.1.9. L-Carnitine and creatine
L-Carnitine and creatine have been trialled in 16 individuals
with FRDA in a placebo-controlled crossover setting [56]. The
two compounds are thought to improve cellular energy
transduction, with L-carnitine in particular thought to enhance
mitochondrial function in FRDA. Participants were adminis-
tered 3 g per day of L-carnitine and 6.75 g per day of creatine
over four months. While both compounds were found to be
well tolerated, no signiﬁcant changes were found in ICARSscores or echocardiographic measures when compared to
placebo [56]. Mitochondrial ATP production improved com-
pared to baseline ( p < 0.03). An open label study in which
individuals with FRDA are administered 2 g/day of acetyl-L-
carnitine over 24 months is ongoing. Outcome measures are
both cardiac and neurological (https://www.clinicaltrials.gov/
ct2/show/NCT01921868).
3.2. Anti-inﬂammatory therapy
3.2.1. Methylprednisolone
It is suggested that the anti-inﬂammatory properties of
steroids may play a role in altering oxidative damage caused
by frataxin deﬁciency. A case report of two individuals with
FRDA and nephrotic syndrome suggested a link between the
two conditions. One of these individuals reported improve-
ment of neurological symptoms after being treated with
corticosteroids [57]. As a result of this initial ﬁnding, an open-
label trial exploring the safety and efﬁcacy of methylprednis-
olone treatment in FRDA is underway. Participants are
receiving six cycles of a reducing dose of oral methylprednis-
olone for 6 days, followed by 22 days without medication prior
to the next cycle (https://www.clinicaltrials.gov/ct2/show/
NCT02424435).
3.3. Iron chelators
3.3.1. Deferiprone
Deﬁciency in frataxin leads to an imbalance in cellular iron
homeostasis [58]. Excess mitochondrial iron has been identi-
ﬁed as a result [59,60]. Iron accumulation in the dentate nuclei
of individuals with FRDA has been reported, leading to
oxidative stress and cell death [61–63].
Deferiprone is an iron chelator that is used to treat iron
overload in several conditions including hemoglobinopathies
[62]. It was ﬁrst studied in nine adolescents with FRDA in a six-
month open label study of 20–30 mg/kg per day of deferiprone
[64]. A decrease in iron accumulation in the dentate nucleus
assessed by MRI was reported (relaxation rate R2* in dentate
nuclei reduced from 18.3 + 1.7 s1 to 15.7  0.7 s1 ( p < 0.002))
after six months of treatment. Small neurological improve-
ments were noted, with ICARS scores reduced by 10% in the
youngest participants [64]. Reduced reactive oxygen species
(ROS) damage to mitochondrial proteins in cells treated with
deferiprone was reported [65], but of concern, the activity of
aconitase, an iron–sulphur protein involved in iron homeosta-
sis [66], was reduced in ﬁbroblasts obtained from individuals
with FRDA following in vitro treatment with deferiprone [67].
A subsequent six-month double-blind, randomised, place-
bo-controlled study assessed the safety and tolerability of
deferiprone at 20, 40, and 60 mg/kg/day in 72 individuals aged
7–35 affected by FRDA [68]. Individuals treated with 20 mg/kg/
day of deferiprone did not demonstrate signiﬁcant changes in
FARS scores however those on 40 mg/kg/day were found to
have a signiﬁcant deterioration in FARS and ICARS scores
compared to those on placebo. Individuals treated with 20 mg/
kg/day and 40 mg/kg/day had a decline in LVMI compared to
those in the placebo group. Deferiprone at 20 mg/kg/day
showed an acceptable safety proﬁle however there were safety
concerns in doses of 40 and 60 mg/kg/day, with reports of
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individuals taking 60 mg/kg/day however the deterioration
in individuals administered 40 mg/kg/day was only shown
during analysis of efﬁcacy data at 6 months [68].
3.4. Frataxin level modiﬁers
3.4.1. Erythropoietin
Erythropoietin (EPO), a hormone that stimulates red blood cell
production [8], has been shown to increase frataxin levels
in vitro [69]. One study found that recombinant human
erythropoietin (rhuEPO) increased frataxin levels in primary
lymphocytes from individuals with FRDA as well as in various
other cell types, including neuronal and cardiac cells [69]. An
open-label clinical pilot study was conducted to ascertain the
role of rhuEPO on frataxin levels in 12 individuals affected by
FRDA [70]. Signiﬁcant increase in frataxin levels was reported
after eight weeks of treatment with 5000 IU of rhuEPO
( p < 0.01). No signiﬁcant neurological improvements, as
measured by the SARA, were reported [70]. A six-month open
label study was then performed where eight individuals with
FRDA received 2000 IU of rhuEPO three times a week [71].
Modest neurological beneﬁt was shown, with improvements
in the FARS and SARA demonstrated. There was a 24% overall
increase in frataxin levels ( p = 0.017) and a reduction in urinary
8-hydroxydeoxyguanosine ( p = 0.012), a marker of oxidative
stress. A randomised placebo-controlled trial of 16 individuals
with FRDA was undertaken over six months [72]. Treatment
consisted of 20,000 IU rhuEPO administered intravenously
every three weeks, 40,000 IU every three weeks and 40,000 IU
every two weeks. While the therapy was well tolerated, there
was no signiﬁcant change in any outcome measure including
frataxin levels and SARA scores. There are concerns about the
extended use of rhuEPO as it can increase red blood cell
production and lead to an increased risk of cardiovascular
events [73].
Carbamylated erythropoietin (CEPO) is a form of modiﬁed
EPO that has minimal erythropoietic properties [74]. The safety
and tolerability of this agent was tested in a randomised
placebo-controlled trial of 36 people with FRDA. While the drug
was well tolerated, which fulﬁlled its primary endpoint of
safety and tolerability, there were no signiﬁcant improve-
ments found in secondary outcome measures including
frataxin levels in peripheral blood mononuclear cells (PBMCs),
FARS and SARA scores [74].
3.4.2. Ubiquitin competitors
It has been determined that the ubiquitin-proteasome system
(UPS) controls frataxin stability [75] leading to development of
a therapeutic approach aimed at preventing the degradation of
frataxin [76]. RNF126 has been identiﬁed as the frataxin E3
ligase that promotes frataxin ubiquitination and degradation.
Inhibition of RNF126 is therefore another potential therapeutic
strategy for FRDA [77]. Further studies exploring this thera-
peutic approach are being planned.
3.4.3. TAT-frataxin
Payne and colleagues have developed an innovative delivery
system named trans-activator transcription (TAT) to transport
synthetic frataxin directly into the mitochondria of mousemodels of FRDA homozygous for a conditional deletion of the
FXN gene [78]. Mean lifespan in these mice was increased by
53%, with improvement also shown in cardiac function,
including increased heart rate, and improved diastolic
function [78]. TAT-Frataxin (now known as CTI-1601) has
since been given orphan drug designation and is currently
being developed as a treatment for FRDA [79].
3.5. Agents that increase FRDA gene expression
3.5.1. Histone deacetylase inhibitors
Histone deacetylase (HDAC) inhibitors reduce epigenetic
silencing of genes by reverting chromatin to an open and
active state for gene transcription. In FRDA, speciﬁc classes of
HDAC inhibitors have been found to increase histone
acetylation and restore frataxin to normal levels in the central
nervous system and heart of FRDA mouse models [80–82]. It
has been shown that a HDAC inhibitor was able to restore
frataxin to normal levels in the central nervous system and
heart of mouse models [83–85]. RG2833, a synthetic HDAC
inhibitor, was tested in an in vitro human FRDA neuronal cell
model derived from patient induced pluripotent stem cells to
study its efﬁcacy in modulating FXN gene expression [85].
Findings revealed an increase in FXN mRNA levels and frataxin
protein. A phase 1 clinical trial of RG2833 in 20 adults with
FRDA was conducted to determine safety and efﬁcacy. The
study comprised four cohorts – two of the cohorts were open
label in design with single 30–120 mg doses, while the other
two were enrolled to randomised, double-blind, placebo-
controlled crossover studies. In the latter two cohorts,
participants received either a single 180 mg dose or placebo,
or two 120 mg doses or placebo. RG2833 was well tolerated and
was found to increase FXN gene expression in circulating
lymphocytes in all but one participant. Upregulation of FXN
mRNA levels in participants on the highest three doses
(120 mg, 180 mg and 240 mg) was demonstrated, with an
average induction of 1.5–1.6 fold shown within 24 h of therapy
administration. While RG2833 was well tolerated, potentially
toxic metabolites of the compound were detected making it
unsuitable for further testing. Additional compounds are
currently being identiﬁed as potential candidates for clinical
trials [86,87].
Nicotinamide (Vitamin B3) is a HDAC inhibitor that has
been studied in FRDA. It has good bioavailability and has been
shown to pass through the blood brain barrier [88]. In an open-
label dose-escalation study, ten individuals with FRDA were
treated with doses of up to 8 g/day of oral nicotinamide [89].
While generally well tolerated, three subjects demonstrated
abnormal liver function test results after taking high doses of
nicotinamide that resolved after the dose was reduced. Daily
dosing at 3.5–6 g demonstrated a signiﬁcant upregulation of
frataxin expression ( p < 0.0001). There were no signiﬁcant
improvements in clinical measures [89]. A randomised,
placebo-controlled, double-blinded study investigating the
efﬁcacy of high dose nicotinamide in FRDA (NICOFA) over two
years is planned [90].
3.5.2. Interferon gamma
Interferon gamma (IFNg) is a cytokine that contributes to iron
metabolism and immune responses. It was shown to increase
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individuals with FRDA [91]. Treatment with IFNg was also
shown to increase frataxin levels in neurons from the dorsal
root ganglia and prevents neuronal degeneration as well as
preventing neurological dysfunction in a FRDA mouse model
[91]. An open-label study of IFNg in 12 children with FRDA was
conducted [92]. The dose of IFNg administered subcutaneously
three times per week was increased from 10 to 50 mg/m2 during
the ﬁrst four weeks and then remained at 50 mg/m2 for the
remaining eight weeks. There was a signiﬁcant improvement
seen in FARS scores ( p = 0.0078), however no other signiﬁcant
changes were observed in the patient reported scales. Change
in frataxin levels in PBMCs and buccal cells did not reach
signiﬁcance [92].
A phase 2 clinical trial testing the safety and efﬁcacy of IFNg
in nine adults over four weeks found modest but non-
signiﬁcant increases in frataxin levels in PBMCs [93]. There
was no signiﬁcant change in the SARA score. A phase 3
multicentre randomised placebo-controlled trial of IFNg in
FRDA has been completed (STEADFAST study) and the primary
endpoint, change in the modiﬁed FARS score, was not met at
26 weeks when compared to placebo [94].
3.5.3. Resveratrol
Resveratrol is a naturally occurring polyphenol with postulat-
ed antioxidant and neuroprotective beneﬁts. Resveratrol was
found to increase frataxin expression in FRDA cell and mouse
models [95]. An open-label 12 week study of 24 individuals
with FRDA (12 receiving 1 g resveratrol daily and 12 receiving
5 g resveratrol daily) showed possible clinical beneﬁt in the
high dose group as measured by FARS, ICARS, a hearing
outcome measure and a speech outcome measure [96]. While
little change was noted in PBMC frataxin protein levels (the
primary outcome measure), high dose resveratrol also resulted
in an improvement in an oxidative stress marker, plasma F2-
isoprostanes. A randomised placebo-controlled trial is
planned [96].
3.5.4. Granulocyte-colony stimulating factor and stem cell
factor
Granulocyte-colony stimulating factor (G-CSF) and stem cell
factor (SCF) are cytokines whose neuroprotective effects have
been explored in a humanised murine model of FRDA [97].
After six months of treatment with monthly subcutaneous
infusions of G-CSF and SCF (200 mg/kg), frataxin levels were
found to have increased [97]. Improvement was also shown
with motor coordination and locomotor activity, along with
increase in neural stem cell numbers and reduction in
inﬂammation. Treatment with G-CSF and SCF therefore look
promising however studies in individuals in FRDA will need to
be conducted to determine safety and efﬁcacy.
4. Gene therapy
Gene replacement therapy is another avenue of treatment that
is being studied and is perhaps the most promising in terms of
correcting frataxin loss in FRDA [98]. There are a number of
strategies for gene correction and cellular targets that are
currently being explored [99]. Perdomini and colleagues usedMck-Cre-FxnL3/L-mice, a conditional cardiac and skeletal
muscle FXN knockout model, and treated the mice with
intravenously administered adeno-associated virus rh10
vector expressing human FXN [100]. They found that cardio-
myopathy onset was averted in these mice. When the
treatment was administered to mice after the onset of cardiac
disease, cardiomyopathy was completely reversed, establish-
ing the potential of gene therapy in the treatment of cardiac
disease in FRDA.
In another study, zinc ﬁnger nucleases were used to excise
the FXN GAA expansion repeat on one allele of cells derived
from individuals with FRDA. This excision lead to an increase
in FXN mRNA and protein expression [101].
Appropriate and adequate systemic delivery to target cells,
immunogenicity of vectors, and safety concerns are common
challenges related to gene therapy approaches. Thorough
examination and assessment of vectors in FRDA disease
models will be imperative to ensure efﬁcacy and safety prior to
human trials [99].
5. Rehabilitation
While the search for effective therapeutic agents is ongoing,
rehabilitation has long been the foundation of managing
physical symptoms and ambulation decline in individuals
with FRDA [102,103]. Despite this, there have been few clinical
studies that have evaluated rehabilitation interventions in
FRDA [104].
An intensive coordinative training programme that con-
sisted of a four-week course of three one-hour sessions each
week was conducted on 16 individuals with degenerative
cerebellar disorders (3 with FRDA) [103]. Exercises in the
programme included static balance, dynamic balance, whole-
body movements for trunk-limb coordination, falling preven-
tion and strategies and movements to treat and prevent
contracture. A signiﬁcant reduction in the SARA score was
demonstrated for all subjects indicating short-term improve-
ments in motor performance was achieved. However individ-
uals with cerebellar ataxia were found to have greater
improvements when compared to those with an afferent
form of ataxia, which included the individuals with FRDA [103].
One year after intervention and using a home exercise training
schedule, a signiﬁcant reduction of ataxia symptoms as
measured by the SARA was found speciﬁcally in the group
with cerebellar ataxias. In the group with afferent ataxia,
including FRDA, the reductions in ataxia symptoms were less
signiﬁcant compared to the cerebellar group and the beneﬁts
did not persist long-term [105].
A retrospective study demonstrated that inpatient rehabil-
itation speciﬁc to FRDA was effective in improving or
preventing decline in function for people with the condition
as measured using the Functional Independence Measure
(FIM) which is an indicator of an individual's ability to perform
activities of daily living [102]. FIM scores were found to
improve signiﬁcantly by a mean of 8.5 points during inpatient
rehabilitation and continued to improve by a mean of 2.0
points following rehabilitation. These results indicate that
inpatient rehabilitation is beneﬁcial in preventing decline in
function in individuals with FRDA [102].
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ducted, examining the effects of a six-week rehabilitation
programme speciﬁcally for individuals with FRDA [106]. The
prescribed rehabilitation programme was individualised and
the study compared an intervention (six weeks of rehabilita-
tion followed by a six-week home exercise programme) group
to a control group (no intervention for six weeks followed by
six weeks of rehabilitation then a six-week home exercise
programme). The intervention portion of the programme was
conducted three times a week and consisted of two to three
hours of physiotherapy, supervised gym exercises and aquatic
physiotherapy. This study showed improvements in function
following short-term rehabilitation in FRDA. While there was
no signiﬁcant difference in the FIM score between the
intervention and control groups, a signiﬁcant change in the
body movement subscale of the Friedreich Ataxia Impact Scale
(FAIS), a patient reported outcome measure, revealed a
signiﬁcant improvement in health and wellbeing in the
intervention group compared to controls ( p = 0.003). There
was a signiﬁcant within-group improvement in the motor
domain of the FIM for the interventional group whereas there
was no such change in the control group. The home exercise
programme was not effective in terms of sustaining frequency
of exercise performance and maintaining the results achieved
during rehabilitation. While the authors concluded that
rehabilitation can play a role in improving health and well-
being in individuals with FRDA, a main limitation was the size
of the study, and therefore a larger, adequately powered study
is required to enable deﬁnitive conclusions to be drawn.
In addition to physical rehabilitation, further evidence is
required to establish the efﬁcacy of occupational therapy and
speech pathology on improving function in FRDA. A review of
the effects of interventions for speech disorder in adults and
children in FRDA and other hereditary ataxias found insufﬁ-
cient and low quality evidence to determine the effectiveness
of any treatment for speech disorders [107]. There is currently
no published evidence on occupational therapy intervention.
6. Conclusion
FRDA is a slowly progressive neurological disorder for which
there is currently no treatment proven to modify the natural
history of the disorder. The exploration for therapeutic agents
has advanced rapidly in the last few decades, with various
pharmacological agents at different stages of development.
The Friedreich's Ataxia Research Alliance (FARA) provides a
comprehensive outline of current therapeutic agents with a
treatment pipeline (http://www.curefa.org/pipeline). At this
time, no study has successfully achieved its stated endpoint
and studies examining the same compounds are generally
inconclusive or conﬂicting. Several issues play a role in this
lack of success including the short length of trials, the
responsiveness of tools used to measure disease progression
in studies as well as the heterogeneity of the populations
studied. It is suggested that studies should target individuals
with FRDA in the early stages of the disease as change is
greatest in this group [108,109]. Further work is needed to
increase the availability of sensitive and responsive outcome
measures that ensures the inclusion in clinical trials of allindividuals with FRDA across the disease trajectory. Research
into gene therapy holds the most promise in the treatment of
this condition however safety and logistic issues will need to
be addressed [8,98].
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